UNCY Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
8.8M
-12.8%
10.1M
+20.2%
8.4M
+16.8%
7.2M
-1.6%
7.3M
R&D
2.2M
-19.4%
2.8M
+73.5%
1.6M
-28.6%
2.3M
-24.1%
3.0M
SG&A
6.6M
-10.3%
7.4M
+7.6%
6.8M
+37.3%
5.0M
+13.6%
4.4M
Operating Income
-8841000
+12.8%
-10140000
-20.2%
-8437000
-16.8%
-7224000
+1.6%
-7342000
EBITDA
-8834000
+12.8%
-10134000
-20.2%
-8429000
-16.8%
-7214000
+1.6%
-7332000
Net Income
-6997000
-306.3%
-1722000
+86.6%
-12823000
+12.6%
-14668000
-144.0%
-6011000
EPS (Basic)
$-0.25
-316.7%
$-0.06
+88.9%
$-0.54
+20.6%
$-0.68
-106.1%
$-0.33
EPS (Diluted)
$-0.25
-316.7%
$-0.06
+88.9%
$-0.54
+23.9%
$-0.71
-115.2%
$-0.33
Shares (Diluted)
28.3M
+5.0%
26.9M
+12.6%
23.9M
+15.0%
20.8M
+15.1%
18.1M
Unicycive Therapeutics (UNCY) — Financials